
PostEra uses its AI platform Proton to speed up the discovery and optimization of small-molecule drug candidates for biopharma partners and internal programs. Proton is an end-to-end machine learning platform that optimizes the Design‑Make‑Test cycle using chemistry foundation models, active learning, synthetic route design, and proprietary chemistry data. The company operates as a B2B SaaS and partnership-led biopharma, running co-discovery collaborations and milestone/royalty deals with pharmaceutical companies while advancing internal pipelines in areas like women’s health, fertility, oncology, obesity, and virology. PostEra integrates state-of-the-art synthesis and ML-driven design to improve candidate quality and reduce iteration time. It partners with large pharma and research institutions at scale, with multiple multi-year collaborations and programs for pandemic preparedness.

PostEra uses its AI platform Proton to speed up the discovery and optimization of small-molecule drug candidates for biopharma partners and internal programs. Proton is an end-to-end machine learning platform that optimizes the Design‑Make‑Test cycle using chemistry foundation models, active learning, synthetic route design, and proprietary chemistry data. The company operates as a B2B SaaS and partnership-led biopharma, running co-discovery collaborations and milestone/royalty deals with pharmaceutical companies while advancing internal pipelines in areas like women’s health, fertility, oncology, obesity, and virology. PostEra integrates state-of-the-art synthesis and ML-driven design to improve candidate quality and reduce iteration time. It partners with large pharma and research institutions at scale, with multiple multi-year collaborations and programs for pandemic preparedness.
What they do: AI-driven drug discovery using Proton, an ML platform for medicinal chemistry
Business model: B2B SaaS and partnership-led co-discovery collaborations plus internal drug programs
Founded: 2019
Funding (reported): $26M total equity/grant financing reported
Key partners: Multi-year collaborations with Pfizer and Amgen; NIH funding
| Company |
|---|
Small-molecule drug discovery and optimization (medicinal chemistry).
2019
Biotechnology Research
$24M
Announced alongside a strategic collaboration with Pfizer
$26,450,000
Last funding date listed in company snapshot data
“Y Combinator; HOF Capital; Pioneer Fund; multiple VC and grant backers reported”